Publishers Alliance

Cancer Management and Research

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients

[Cancer Management and Research] A comparison of the ABCD regimen for newly diagnosed multiple myeloma with the standard BD regimen sought to determine efficacy and safety of the former regimen, as relapse or refractory disease is common with the standard BD regimen.

Next post in Publishers Alliance